You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live



▲  2nd Inning 0 outs

Mass. Movers

Cambridge’s Idenix up on pipeline update

Continue reading below

Cambridge’s Idenix Pharmaceuticals Inc. reported third-quarter revenue of less than $0.1 million, compared to $32.3 million a year ago. The company said it lost $34 million, compared to a profit of $4.3 million, last year. But investors showed optimism after Idenix gave an update on its product pipeline. It said that its hepatitis C treatment has received approval to enter clinical trials in Canada and Belgium, and that all patients had completed enrollment in the first phase of its midstage trial involving samatasvir, its NS5A inhibitor.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of